Euroapi（EAPIP）株式概要Euroapi S.A.は、ヒトおよび動物用医薬品の製剤に使用される原薬および中間体の開発、製造、販売、流通を行っている。 詳細EAPIP ファンダメンタル分析スノーフレーク・スコア評価4/6将来の成長3/6過去の実績0/6財務の健全性5/6配当金0/6報酬当社が推定した公正価値より29.3%で取引されている 収益は年間78.29%増加すると予測されています リスク分析株式の流動性は非常に低い すべてのリスクチェックを見るEAPIP Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value€Current Price€1.2994.3% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-211m1b2016201920222025202620282031Revenue €965.9mEarnings €141.1mAdvancedSet Fair ValueView all narrativesEuroapi S.A. 競合他社ECO Animal Health GroupSymbol: AIM:EAHMarket cap: UK£65.7mAnimalcare GroupSymbol: AIM:ANCRMarket cap: UK£228.9mAllergy TherapeuticsSymbol: AIM:AGYMarket cap: UK£600.3mShield TherapeuticsSymbol: AIM:STXMarket cap: UK£67.8m価格と性能株価の高値、安値、推移の概要Euroapi過去の株価現在の株価€1.2952週高値€3.1652週安値€1.29ベータ0.961ヶ月の変化0%3ヶ月変化n/a1年変化n/a3年間の変化-87.85%5年間の変化n/aIPOからの変化-91.10%最新ニュースお知らせ • Mar 05Euroapi S.A. Provides Earnings Guidance for the Fy 2026Euroapi S.A. provided earnings guidance for the Fiscal Year 2026. For the period, the company expects Net Sales to decrease around 10% on a comparable basis compared to 2025 due to the negative impact of portfolio rationalization (€(55) to (60) million negative impact expected in 202615), reduced demand from Sanofi, and the discontinuation of commercial CDMO contracts.お知らせ • Oct 02EUROAPI Announces Step Down of Rodolfo J. Savitzky as Independent Director and Chair of the Audit Committee, Effective December 31, 2025EUROAPI announced that Rodolfo J. Savitzky will step down from his role as EUROAPI’s Independent Director and Chair of the Audit Committee, effective December 31, 2025. The search for a new Independent Director has been initiated, and Rodolfo J. Savitzky’s successor is expected to be appointed before the end of the year.お知らせ • Jul 30+ 1 more updateEuroapi S.A. to Report Fiscal Year 2025 Results on Mar 03, 2026Euroapi S.A. announced that they will report fiscal year 2025 results on Mar 03, 2026お知らせ • Jul 02Particle Dynamics, Inc. acquired EUROAPI UK Ltd from Euroapi S.A. (ENXTPA:EAPI).Particle Dynamics, Inc. acquired EUROAPI UK Ltd from Euroapi S.A. (ENXTPA:EAPI) on June 30, 2025. The transaction was completed under financial terms reflecting the fair value of the shares sold. All operations and associated commitments related to the company will be transferred to Particle Dynamics. The transaction is expected to have a limited impact on EUROAPI’s H1 2025 consolidated financial statements. Particle Dynamics, Inc. completed the acquisition of EUROAPI UK Ltd from Euroapi S.A. (ENXTPA:EAPI) on June 30, 2025.お知らせ • Apr 17Euroapi S.A., Annual General Meeting, May 21, 2025Euroapi S.A., Annual General Meeting, May 21, 2025. Location: theatre traversiere, 15 bis rue traversiere, paris Franceお知らせ • Mar 04Euroapi S.A. Provides Earnings Guidance for the Full Year 2025Euroapi S.A. provided earnings guidance for the full year 2025. For the year, the company expects Net Sales are expected to range from slightly decreasing to steady. This should notably be driven by solid growth in API sales to clients other than Sanofi, particularly in HP APIs, and Opiates, and by double-digit growth in sales from early-phase CDMO, offset by continued reduced API demand from Sanofi, particularly for Sevelamer, a slight decrease in Vitamin B12 sales, and the discontinuation of several pre-carve-out mature CMO projects.最新情報をもっと見るRecent updatesお知らせ • Mar 05Euroapi S.A. Provides Earnings Guidance for the Fy 2026Euroapi S.A. provided earnings guidance for the Fiscal Year 2026. For the period, the company expects Net Sales to decrease around 10% on a comparable basis compared to 2025 due to the negative impact of portfolio rationalization (€(55) to (60) million negative impact expected in 202615), reduced demand from Sanofi, and the discontinuation of commercial CDMO contracts.お知らせ • Oct 02EUROAPI Announces Step Down of Rodolfo J. Savitzky as Independent Director and Chair of the Audit Committee, Effective December 31, 2025EUROAPI announced that Rodolfo J. Savitzky will step down from his role as EUROAPI’s Independent Director and Chair of the Audit Committee, effective December 31, 2025. The search for a new Independent Director has been initiated, and Rodolfo J. Savitzky’s successor is expected to be appointed before the end of the year.お知らせ • Jul 30+ 1 more updateEuroapi S.A. to Report Fiscal Year 2025 Results on Mar 03, 2026Euroapi S.A. announced that they will report fiscal year 2025 results on Mar 03, 2026お知らせ • Jul 02Particle Dynamics, Inc. acquired EUROAPI UK Ltd from Euroapi S.A. (ENXTPA:EAPI).Particle Dynamics, Inc. acquired EUROAPI UK Ltd from Euroapi S.A. (ENXTPA:EAPI) on June 30, 2025. The transaction was completed under financial terms reflecting the fair value of the shares sold. All operations and associated commitments related to the company will be transferred to Particle Dynamics. The transaction is expected to have a limited impact on EUROAPI’s H1 2025 consolidated financial statements. Particle Dynamics, Inc. completed the acquisition of EUROAPI UK Ltd from Euroapi S.A. (ENXTPA:EAPI) on June 30, 2025.お知らせ • Apr 17Euroapi S.A., Annual General Meeting, May 21, 2025Euroapi S.A., Annual General Meeting, May 21, 2025. Location: theatre traversiere, 15 bis rue traversiere, paris Franceお知らせ • Mar 04Euroapi S.A. Provides Earnings Guidance for the Full Year 2025Euroapi S.A. provided earnings guidance for the full year 2025. For the year, the company expects Net Sales are expected to range from slightly decreasing to steady. This should notably be driven by solid growth in API sales to clients other than Sanofi, particularly in HP APIs, and Opiates, and by double-digit growth in sales from early-phase CDMO, offset by continued reduced API demand from Sanofi, particularly for Sevelamer, a slight decrease in Vitamin B12 sales, and the discontinuation of several pre-carve-out mature CMO projects.お知らせ • Oct 16+ 1 more updateEUROAPI Announces CFO ChangesOlivier Falut has been appointed EUROAPI’s Chief Financial Officer, effective October 17, 2024. He is taking over from Evelyne Nguyen, who will remain within the company until the end of October to ensure a smooth transition. Olivier Falut joins EUROAPI with close to 30 years of experience in management and finance in the industrial sector. Throughout his career, he held various financial positions in listed and non-listed companies, such as Fareva, Limagrain (including Vilmorin & Cie), Lactalis and Bel. Olivier Falut started his career in the financial audit sector, mainly at Ernst & Young in France and then in the United States. In 2001, he joined Bosch France as head of accounting and pursued his career as accounting director at Bel in 2003. In 2008, he joined Oberthur Technologies as CFO for the main business unit before moving to Lactalis (2012-2017) as head of group financial control. Since 2017, he has held CFO positions in various companies including Sodiaal, Segula Technologies, Limagrain and Fareva. Olivier Falut is a graduate from ESSEC business school and holds master’s degrees in business law. He also graduated from the French bar exam.お知らせ • Sep 13Euroapi S.A. to Report Fiscal Year 2024 Results on Mar 03, 2025Euroapi S.A. announced that they will report fiscal year 2024 results on Mar 03, 2025お知らせ • Jul 30+ 1 more updateEuroapi S.A. to Report First Half, 2025 Results on Jul 29, 2025Euroapi S.A. announced that they will report first half, 2025 results on Jul 29, 2025お知らせ • May 15+ 1 more updateEUROAPI Appoints Evelyne Nguyen as Chief Financial OfficerEvelyne Nguyen has been appointed EUROAPI’s Chief Financial Officer, effective May 14, 2024. She is taking over from Antoine Delcour, who is leaving the company to pursue new endeavors. Antoine will remain within the company until the end of June to ensure a smooth transition. Evelyne joins EUROAPI with over 30 years of experience in senior management and finance in the pharmaceutical and life science industries. Throughout her career, Eelyne held various finance, strategy, and management positions in listed and non-listed companies, such as Bristol Myers Squibb, SAUR, and LFB (Laboratoire Français du Fractionnement et des Biotechnologies). She has recently ssisted Biotech and Medtech companies with their strategic and financial projects. A graduate of ISG (Institut Supérieur de Gestion) and Stanford University Executive Program, Evelyne Nguyen started her career in Controlling and Finance for various international companies such as Coca-Cola and Schweppes. In 1987, she joined Bristol Myers Squibb France as a Business Planning and Financial Analysis Manager and pursued her career in Finance at SAUR (formerly Bouygues Group) in 1992. In 2007, she joined LFB, a biopharmaceutical company specialized in plasma derived medicinal products, and served during 12 years as CFO-Executive Vice President Finance and Strategy, supervising Strategic Planning, M&A, Corporate Finance, Internal Audit, and Information Systems. As a member of the Executive Committee, she was appointed Executive Vice President of Development and Biomanufacturing in 2010, in charge, notably, of CDMO business development, manufacturing scale up and strategic alliances. Evelyne has international experience with Europe, US and Asia. Since 2013, Evelyne Nguyen has worked as Finance, Strategy, and Business Development Advisor, supporting healthcare companies in several areas, including IPOs, debt and fund raising, strategic roadmap, business plan, and M&A.お知らせ • Apr 10Euroapi S.A. Announces Executive and Executive Committee ChangesEUROAPI announced a streamlining of its Executive Committee around operational functions in order to improve focus and efficiency. As part of this move, Guillaume Rosso has been appointed as Chief Commercial Officer, succeeding Laurent Alexandre who has decided to pursue other opportunities outside of the company. The new Executive Committee will be composed of: Antoine Delcour,Chief Financial Officer, Thierry Durand,Chief R&D Officer, Ute Herzog, Chief Human Resources Officer, Cécile Maupas, Chief CDMO Officer, Guillaume Rosso, Chief Commercial Officer, David Seignolle, Chief Operating Officer.New Risk • Mar 06New minor risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow. Free cash flow: -€128m This is considered a minor risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Shares are highly illiquid. Minor Risk Less than 1 year of cash runway based on current free cash flow (-€128m).Board Change • Mar 06High number of new and inexperienced directorsThere are 12 new directors who have joined the board in the last 3 years. The company's board is composed of: 12 new directors. No experienced directors. No highly experienced directors. Nominating Director Adeline Franc is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.お知らせ • Nov 29EUROAPI Announces Executive ChangesEUROAPI announced the appointment of David Seignolle as Chief Operating Officer, succeeding Eric Berger, and Marion Santin as Chief Legal, Compliance, and IP Officer, both joining the company’s Executive Committee. In his new role, David Seignolle will lead the transformation of the Industrial Operations organization, focusing on reinforcing robustness and compliance on the entire end-to-end supply chain whilst bringing relevant innovation and product development to support the company's ambition. He will actively oversee the industrial execution of the strategic review announced on October 9, 2023. David Seignolle, a French citizen, joins EUROAPI from Bain & Company where he served as Expert Partner in the Healthcare Practice. Prior to this, David spent 6 years at TEVA where he held several positions such as Head of Operations for Teva API in Italy and Mexico, Vice President Global Supply Chain API and Biologics or Site General Manager. David has also served 5 years at McKinsey & Company in France and in the US where he was focusing on Pharma Operations after beginning his career in Procurement at Toyota Motor Europe. David has a degree in Mechanical Engineering & Industrial Science as well as a postmaster degree in International Procurement Management. Marion Santin, a French citizen, began her career as an associate in law firms, first at Kramer Levin Naftalis & Frankel LLP and then at DLA Piper. She then joined Sanofi in 2006, where she first held the position of Industrial Affairs Legal Manager, then Alliances & Partnerships Legal Director, Mergers & Acquisitions Legal Director before becoming Commercial Operations Legal Director for the legal teams based in Asia, the Middle East, India, Hong Kong and Taiwan. Marion holds an Advanced Degree in Business Law and a Magistère in Business Law from the University of Paris I - Panthéon-Sorbonne. Marion is also a member of the Paris Bar.お知らせ • Nov 22Euroapi S.A. (ENXTPA:EAPI) completed the acquisition of Bianogmp Gmbh.Euroapi S.A. (ENXTPA:EAPI) signed an agreement to acquire Bianogmp Gmbh for €10 million on August 29, 2023. The total consideration for the transaction is approximately €10 million, including the acquisition price (upfront payment and deferred consideration) and Capex aimed to increase Biano’s capacity to address larger scale and more complex projects. Biano will retain its corporate brand and become a EUROAPI company. The closing of the transaction is subject to customary conditions precedent and is expected in the fourth quarter of 2023.Euroapi S.A. (ENXTPA:EAPI) completed the acquisition of Bianogmp Gmbh on November 21, 2023. As planned, Biano will retain its corporate brand and become a EUROAPI company.お知らせ • Oct 26+ 1 more updateEuroapi S.A. Announces Executive Changes, Effective October 30, 2023EUROAPI S.A’s Board of Directors met on October 25, 2023, and decided that Karl Rotthier will step down as Chief Executive Officer, effective October 30, 2023. The Board has launched a search for a new Chief Executive Officer. Consequently, it has appointed Viviane Monges, EUROAPI’s current Chair of the Board, as Chief Executive Officer until a permanent successor has been appointed. She will remain EUROAPI’s Chair of the Board. Viviane Monges is an experienced Finance Executive and Director and has worked in several business sectors and more than 25 years in the pharmaceutical industry. She served as Chief Financial Officer of the group Galderma S.A., a multinational company specializing in dermatology. She was Chief Financial Officer of the EMEA region and then World Chief Financial Officer for the OTC division at Novartis. At Wyeth Pharmaceuticals/Pfizer, sheheld the position of Chief Financial Officer of the Global Pharma Business unit. She served on several Pharma companies' boards and is currently a member of the Board of Novo Holdings, Ferring Pharmaceuticals and Pharvaris.Valuation Update With 7 Day Price Move • Oct 11Investor sentiment deteriorates as stock falls 53%After last week's 53% share price decline to €5.53, the stock trades at a forward P/E ratio of 8x. Average forward P/E is 15x in the Pharmaceuticals industry in the United Kingdom. Total loss to shareholders of 69% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €9.63 per share.お知らせ • Oct 10Euroapi S.A. Provides Sales Guidance for the Full-Year 2023Euroapi S.A. provided sales guidance for the full-year 2023. For the year Net Sales are now expected to grow between +3% and +5%, compared to +7% to +8% previously. The slowdown of full-year 2023 Net Sales growth compared to initial expectations is primarily driven by: For API Solutions: the price optimization strategy has recently been impaired by the changing market environment, with pricing pressure resulting from lower overall inflation and destocking programs from some of customers. For the CDMO activities: Net Sales are expected to grow at a slower pace than anticipated due to weaker sales recognition than expected in the fourth quarter. This is notably driven by Biotech companies, with projects delayed, put on hold, or downsized due to funding issues.お知らせ • Aug 31Euroapi S.A. (ENXTPA:EAPI) signed an agreement to acquire Bianogmp Gmbh for €10 million.Euroapi S.A. (ENXTPA:EAPI) signed an agreement to acquire Bianogmp Gmbh for €10 million on August 29, 2023. The total consideration for the transaction is approximately €10 million, including the acquisition price (upfront payment and deferred consideration) and Capex aimed to increase Biano’s capacity to address larger scale and more complex projects. Biano will retain its corporate brand and become a EUROAPI company. The closing of the transaction is subject to customary conditions precedent and is expected in the fourth quarter of 2023.Reported Earnings • Aug 02First half 2023 earnings released: EPS: €0.67 (vs €0.18 in 1H 2022)First half 2023 results: EPS: €0.67 (up from €0.18 in 1H 2022). Revenue: €498.5m (up 2.6% from 1H 2022). Net income: €62.8m (up 276% from 1H 2022). Profit margin: 13% (up from 3.4% in 1H 2022). Revenue is forecast to grow 6.7% p.a. on average during the next 3 years, compared to a 6.7% growth forecast for the Pharmaceuticals industry in the United Kingdom.お知らせ • Aug 01+ 2 more updatesEuroapi S.A. to Report Fiscal Year 2023 Results on Feb 29, 2024Euroapi S.A. announced that they will report fiscal year 2023 results Pre-Market on Feb 29, 2024Reported Earnings • Mar 10Full year 2022 earnings releasedFull year 2022 results: Revenue: €980.9m (up 9.9% from FY 2021). Net loss: €15.0m (loss narrowed 5.1% from FY 2021). Revenue is forecast to grow 5.2% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Pharmaceuticals industry in the United Kingdom.お知らせ • Jan 12EUROAPI Announces Resignation of Corinne Le Goff as an Independent Member on the Board of DirectorsThe board of directors of EUROAPI announced Corinne Le Goff, after serving as an independent member on the board of directors since May 6, 2022, has resigned from her directorship as of January 11, 2023.Buying Opportunity • Dec 08Now 29% undervalued after recent price dropOver the last 90 days, the stock is down 13%. The fair value is estimated to be €20.26, however this is not to be taken as a buy recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 5.4% per annum. Earnings is also forecast to grow by 32% per annum over the same time period.Buying Opportunity • Nov 17Now 20% undervaluedOver the last 90 days, the stock is up 9.1%. The fair value is estimated to be €21.98, however this is not to be taken as a buy recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 5.4% per annum. Earnings is also forecast to grow by 31% per annum over the same time period.お知らせ • Sep 01Euroapi S.A. to Report Fiscal Year 2022 Results on Mar 08, 2023Euroapi S.A. announced that they will report fiscal year 2022 results Pre-Market on Mar 08, 2023株主還元EAPIPGB PharmaceuticalsGB 市場7D0%2.2%0.3%1Yn/a26.1%18.8%株主還元を見る業界別リターン: EAPIPがUK Pharmaceuticals業界に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。リターン対市場: EAPIP UK市場に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。価格変動Is EAPIP's price volatile compared to industry and market?EAPIP volatilityEAPIP Average Weekly Movementn/aPharmaceuticals Industry Average Movement6.1%Market Average Movement5.7%10% most volatile stocks in GB Market11.9%10% least volatile stocks in GB Market3.1%安定した株価: EAPIPの株価は、 UK市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 過去 1 年間のEAPIPのボラティリティの変化を判断するには データが不十分です。会社概要設立従業員CEO（最高経営責任者ウェブサイト20202,961David Seignollewww.euroapi.com/enEuroapi S.A.は、ヒトおよび動物用医薬品の製剤化に使用される原薬および中間体の開発、製造、販売、マーケティングを行っている。固相化学、粒子工学、微生物発酵、低分子合成、プロスタグランジン、ステロイドとホルモン、アヘン剤と規制薬物、脂質を使用するさまざまなクラスのタイドの受託開発製造組織を提供している。同社は2020年に法人化され、フランスのパリを拠点としている。もっと見るEuroapi S.A. 基礎のまとめEuroapi の収益と売上を時価総額と比較するとどうか。EAPIP 基礎統計学時価総額€136.50m収益（TTM）-€211.20m売上高(TTM)€852.60m0.2xP/Sレシオ-0.7xPER（株価収益率EAPIP は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計EAPIP 損益計算書（TTM）収益€852.60m売上原価€707.70m売上総利益€144.90mその他の費用€356.10m収益-€211.20m直近の収益報告Dec 31, 2025次回決算日Jul 28, 2026一株当たり利益（EPS）-2.22グロス・マージン17.00%純利益率-24.77%有利子負債／自己資本比率5.8%EAPIP の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/21 22:26終値2026/03/19 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Euroapi S.A. 5 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。11 アナリスト機関Justin Steven SmithBernsteinPatrick Andrew WoodBofA Global ResearchFynn ScherzlerDeutsche Bank8 その他のアナリストを表示
お知らせ • Mar 05Euroapi S.A. Provides Earnings Guidance for the Fy 2026Euroapi S.A. provided earnings guidance for the Fiscal Year 2026. For the period, the company expects Net Sales to decrease around 10% on a comparable basis compared to 2025 due to the negative impact of portfolio rationalization (€(55) to (60) million negative impact expected in 202615), reduced demand from Sanofi, and the discontinuation of commercial CDMO contracts.
お知らせ • Oct 02EUROAPI Announces Step Down of Rodolfo J. Savitzky as Independent Director and Chair of the Audit Committee, Effective December 31, 2025EUROAPI announced that Rodolfo J. Savitzky will step down from his role as EUROAPI’s Independent Director and Chair of the Audit Committee, effective December 31, 2025. The search for a new Independent Director has been initiated, and Rodolfo J. Savitzky’s successor is expected to be appointed before the end of the year.
お知らせ • Jul 30+ 1 more updateEuroapi S.A. to Report Fiscal Year 2025 Results on Mar 03, 2026Euroapi S.A. announced that they will report fiscal year 2025 results on Mar 03, 2026
お知らせ • Jul 02Particle Dynamics, Inc. acquired EUROAPI UK Ltd from Euroapi S.A. (ENXTPA:EAPI).Particle Dynamics, Inc. acquired EUROAPI UK Ltd from Euroapi S.A. (ENXTPA:EAPI) on June 30, 2025. The transaction was completed under financial terms reflecting the fair value of the shares sold. All operations and associated commitments related to the company will be transferred to Particle Dynamics. The transaction is expected to have a limited impact on EUROAPI’s H1 2025 consolidated financial statements. Particle Dynamics, Inc. completed the acquisition of EUROAPI UK Ltd from Euroapi S.A. (ENXTPA:EAPI) on June 30, 2025.
お知らせ • Apr 17Euroapi S.A., Annual General Meeting, May 21, 2025Euroapi S.A., Annual General Meeting, May 21, 2025. Location: theatre traversiere, 15 bis rue traversiere, paris France
お知らせ • Mar 04Euroapi S.A. Provides Earnings Guidance for the Full Year 2025Euroapi S.A. provided earnings guidance for the full year 2025. For the year, the company expects Net Sales are expected to range from slightly decreasing to steady. This should notably be driven by solid growth in API sales to clients other than Sanofi, particularly in HP APIs, and Opiates, and by double-digit growth in sales from early-phase CDMO, offset by continued reduced API demand from Sanofi, particularly for Sevelamer, a slight decrease in Vitamin B12 sales, and the discontinuation of several pre-carve-out mature CMO projects.
お知らせ • Mar 05Euroapi S.A. Provides Earnings Guidance for the Fy 2026Euroapi S.A. provided earnings guidance for the Fiscal Year 2026. For the period, the company expects Net Sales to decrease around 10% on a comparable basis compared to 2025 due to the negative impact of portfolio rationalization (€(55) to (60) million negative impact expected in 202615), reduced demand from Sanofi, and the discontinuation of commercial CDMO contracts.
お知らせ • Oct 02EUROAPI Announces Step Down of Rodolfo J. Savitzky as Independent Director and Chair of the Audit Committee, Effective December 31, 2025EUROAPI announced that Rodolfo J. Savitzky will step down from his role as EUROAPI’s Independent Director and Chair of the Audit Committee, effective December 31, 2025. The search for a new Independent Director has been initiated, and Rodolfo J. Savitzky’s successor is expected to be appointed before the end of the year.
お知らせ • Jul 30+ 1 more updateEuroapi S.A. to Report Fiscal Year 2025 Results on Mar 03, 2026Euroapi S.A. announced that they will report fiscal year 2025 results on Mar 03, 2026
お知らせ • Jul 02Particle Dynamics, Inc. acquired EUROAPI UK Ltd from Euroapi S.A. (ENXTPA:EAPI).Particle Dynamics, Inc. acquired EUROAPI UK Ltd from Euroapi S.A. (ENXTPA:EAPI) on June 30, 2025. The transaction was completed under financial terms reflecting the fair value of the shares sold. All operations and associated commitments related to the company will be transferred to Particle Dynamics. The transaction is expected to have a limited impact on EUROAPI’s H1 2025 consolidated financial statements. Particle Dynamics, Inc. completed the acquisition of EUROAPI UK Ltd from Euroapi S.A. (ENXTPA:EAPI) on June 30, 2025.
お知らせ • Apr 17Euroapi S.A., Annual General Meeting, May 21, 2025Euroapi S.A., Annual General Meeting, May 21, 2025. Location: theatre traversiere, 15 bis rue traversiere, paris France
お知らせ • Mar 04Euroapi S.A. Provides Earnings Guidance for the Full Year 2025Euroapi S.A. provided earnings guidance for the full year 2025. For the year, the company expects Net Sales are expected to range from slightly decreasing to steady. This should notably be driven by solid growth in API sales to clients other than Sanofi, particularly in HP APIs, and Opiates, and by double-digit growth in sales from early-phase CDMO, offset by continued reduced API demand from Sanofi, particularly for Sevelamer, a slight decrease in Vitamin B12 sales, and the discontinuation of several pre-carve-out mature CMO projects.
お知らせ • Oct 16+ 1 more updateEUROAPI Announces CFO ChangesOlivier Falut has been appointed EUROAPI’s Chief Financial Officer, effective October 17, 2024. He is taking over from Evelyne Nguyen, who will remain within the company until the end of October to ensure a smooth transition. Olivier Falut joins EUROAPI with close to 30 years of experience in management and finance in the industrial sector. Throughout his career, he held various financial positions in listed and non-listed companies, such as Fareva, Limagrain (including Vilmorin & Cie), Lactalis and Bel. Olivier Falut started his career in the financial audit sector, mainly at Ernst & Young in France and then in the United States. In 2001, he joined Bosch France as head of accounting and pursued his career as accounting director at Bel in 2003. In 2008, he joined Oberthur Technologies as CFO for the main business unit before moving to Lactalis (2012-2017) as head of group financial control. Since 2017, he has held CFO positions in various companies including Sodiaal, Segula Technologies, Limagrain and Fareva. Olivier Falut is a graduate from ESSEC business school and holds master’s degrees in business law. He also graduated from the French bar exam.
お知らせ • Sep 13Euroapi S.A. to Report Fiscal Year 2024 Results on Mar 03, 2025Euroapi S.A. announced that they will report fiscal year 2024 results on Mar 03, 2025
お知らせ • Jul 30+ 1 more updateEuroapi S.A. to Report First Half, 2025 Results on Jul 29, 2025Euroapi S.A. announced that they will report first half, 2025 results on Jul 29, 2025
お知らせ • May 15+ 1 more updateEUROAPI Appoints Evelyne Nguyen as Chief Financial OfficerEvelyne Nguyen has been appointed EUROAPI’s Chief Financial Officer, effective May 14, 2024. She is taking over from Antoine Delcour, who is leaving the company to pursue new endeavors. Antoine will remain within the company until the end of June to ensure a smooth transition. Evelyne joins EUROAPI with over 30 years of experience in senior management and finance in the pharmaceutical and life science industries. Throughout her career, Eelyne held various finance, strategy, and management positions in listed and non-listed companies, such as Bristol Myers Squibb, SAUR, and LFB (Laboratoire Français du Fractionnement et des Biotechnologies). She has recently ssisted Biotech and Medtech companies with their strategic and financial projects. A graduate of ISG (Institut Supérieur de Gestion) and Stanford University Executive Program, Evelyne Nguyen started her career in Controlling and Finance for various international companies such as Coca-Cola and Schweppes. In 1987, she joined Bristol Myers Squibb France as a Business Planning and Financial Analysis Manager and pursued her career in Finance at SAUR (formerly Bouygues Group) in 1992. In 2007, she joined LFB, a biopharmaceutical company specialized in plasma derived medicinal products, and served during 12 years as CFO-Executive Vice President Finance and Strategy, supervising Strategic Planning, M&A, Corporate Finance, Internal Audit, and Information Systems. As a member of the Executive Committee, she was appointed Executive Vice President of Development and Biomanufacturing in 2010, in charge, notably, of CDMO business development, manufacturing scale up and strategic alliances. Evelyne has international experience with Europe, US and Asia. Since 2013, Evelyne Nguyen has worked as Finance, Strategy, and Business Development Advisor, supporting healthcare companies in several areas, including IPOs, debt and fund raising, strategic roadmap, business plan, and M&A.
お知らせ • Apr 10Euroapi S.A. Announces Executive and Executive Committee ChangesEUROAPI announced a streamlining of its Executive Committee around operational functions in order to improve focus and efficiency. As part of this move, Guillaume Rosso has been appointed as Chief Commercial Officer, succeeding Laurent Alexandre who has decided to pursue other opportunities outside of the company. The new Executive Committee will be composed of: Antoine Delcour,Chief Financial Officer, Thierry Durand,Chief R&D Officer, Ute Herzog, Chief Human Resources Officer, Cécile Maupas, Chief CDMO Officer, Guillaume Rosso, Chief Commercial Officer, David Seignolle, Chief Operating Officer.
New Risk • Mar 06New minor risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow. Free cash flow: -€128m This is considered a minor risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Shares are highly illiquid. Minor Risk Less than 1 year of cash runway based on current free cash flow (-€128m).
Board Change • Mar 06High number of new and inexperienced directorsThere are 12 new directors who have joined the board in the last 3 years. The company's board is composed of: 12 new directors. No experienced directors. No highly experienced directors. Nominating Director Adeline Franc is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
お知らせ • Nov 29EUROAPI Announces Executive ChangesEUROAPI announced the appointment of David Seignolle as Chief Operating Officer, succeeding Eric Berger, and Marion Santin as Chief Legal, Compliance, and IP Officer, both joining the company’s Executive Committee. In his new role, David Seignolle will lead the transformation of the Industrial Operations organization, focusing on reinforcing robustness and compliance on the entire end-to-end supply chain whilst bringing relevant innovation and product development to support the company's ambition. He will actively oversee the industrial execution of the strategic review announced on October 9, 2023. David Seignolle, a French citizen, joins EUROAPI from Bain & Company where he served as Expert Partner in the Healthcare Practice. Prior to this, David spent 6 years at TEVA where he held several positions such as Head of Operations for Teva API in Italy and Mexico, Vice President Global Supply Chain API and Biologics or Site General Manager. David has also served 5 years at McKinsey & Company in France and in the US where he was focusing on Pharma Operations after beginning his career in Procurement at Toyota Motor Europe. David has a degree in Mechanical Engineering & Industrial Science as well as a postmaster degree in International Procurement Management. Marion Santin, a French citizen, began her career as an associate in law firms, first at Kramer Levin Naftalis & Frankel LLP and then at DLA Piper. She then joined Sanofi in 2006, where she first held the position of Industrial Affairs Legal Manager, then Alliances & Partnerships Legal Director, Mergers & Acquisitions Legal Director before becoming Commercial Operations Legal Director for the legal teams based in Asia, the Middle East, India, Hong Kong and Taiwan. Marion holds an Advanced Degree in Business Law and a Magistère in Business Law from the University of Paris I - Panthéon-Sorbonne. Marion is also a member of the Paris Bar.
お知らせ • Nov 22Euroapi S.A. (ENXTPA:EAPI) completed the acquisition of Bianogmp Gmbh.Euroapi S.A. (ENXTPA:EAPI) signed an agreement to acquire Bianogmp Gmbh for €10 million on August 29, 2023. The total consideration for the transaction is approximately €10 million, including the acquisition price (upfront payment and deferred consideration) and Capex aimed to increase Biano’s capacity to address larger scale and more complex projects. Biano will retain its corporate brand and become a EUROAPI company. The closing of the transaction is subject to customary conditions precedent and is expected in the fourth quarter of 2023.Euroapi S.A. (ENXTPA:EAPI) completed the acquisition of Bianogmp Gmbh on November 21, 2023. As planned, Biano will retain its corporate brand and become a EUROAPI company.
お知らせ • Oct 26+ 1 more updateEuroapi S.A. Announces Executive Changes, Effective October 30, 2023EUROAPI S.A’s Board of Directors met on October 25, 2023, and decided that Karl Rotthier will step down as Chief Executive Officer, effective October 30, 2023. The Board has launched a search for a new Chief Executive Officer. Consequently, it has appointed Viviane Monges, EUROAPI’s current Chair of the Board, as Chief Executive Officer until a permanent successor has been appointed. She will remain EUROAPI’s Chair of the Board. Viviane Monges is an experienced Finance Executive and Director and has worked in several business sectors and more than 25 years in the pharmaceutical industry. She served as Chief Financial Officer of the group Galderma S.A., a multinational company specializing in dermatology. She was Chief Financial Officer of the EMEA region and then World Chief Financial Officer for the OTC division at Novartis. At Wyeth Pharmaceuticals/Pfizer, sheheld the position of Chief Financial Officer of the Global Pharma Business unit. She served on several Pharma companies' boards and is currently a member of the Board of Novo Holdings, Ferring Pharmaceuticals and Pharvaris.
Valuation Update With 7 Day Price Move • Oct 11Investor sentiment deteriorates as stock falls 53%After last week's 53% share price decline to €5.53, the stock trades at a forward P/E ratio of 8x. Average forward P/E is 15x in the Pharmaceuticals industry in the United Kingdom. Total loss to shareholders of 69% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €9.63 per share.
お知らせ • Oct 10Euroapi S.A. Provides Sales Guidance for the Full-Year 2023Euroapi S.A. provided sales guidance for the full-year 2023. For the year Net Sales are now expected to grow between +3% and +5%, compared to +7% to +8% previously. The slowdown of full-year 2023 Net Sales growth compared to initial expectations is primarily driven by: For API Solutions: the price optimization strategy has recently been impaired by the changing market environment, with pricing pressure resulting from lower overall inflation and destocking programs from some of customers. For the CDMO activities: Net Sales are expected to grow at a slower pace than anticipated due to weaker sales recognition than expected in the fourth quarter. This is notably driven by Biotech companies, with projects delayed, put on hold, or downsized due to funding issues.
お知らせ • Aug 31Euroapi S.A. (ENXTPA:EAPI) signed an agreement to acquire Bianogmp Gmbh for €10 million.Euroapi S.A. (ENXTPA:EAPI) signed an agreement to acquire Bianogmp Gmbh for €10 million on August 29, 2023. The total consideration for the transaction is approximately €10 million, including the acquisition price (upfront payment and deferred consideration) and Capex aimed to increase Biano’s capacity to address larger scale and more complex projects. Biano will retain its corporate brand and become a EUROAPI company. The closing of the transaction is subject to customary conditions precedent and is expected in the fourth quarter of 2023.
Reported Earnings • Aug 02First half 2023 earnings released: EPS: €0.67 (vs €0.18 in 1H 2022)First half 2023 results: EPS: €0.67 (up from €0.18 in 1H 2022). Revenue: €498.5m (up 2.6% from 1H 2022). Net income: €62.8m (up 276% from 1H 2022). Profit margin: 13% (up from 3.4% in 1H 2022). Revenue is forecast to grow 6.7% p.a. on average during the next 3 years, compared to a 6.7% growth forecast for the Pharmaceuticals industry in the United Kingdom.
お知らせ • Aug 01+ 2 more updatesEuroapi S.A. to Report Fiscal Year 2023 Results on Feb 29, 2024Euroapi S.A. announced that they will report fiscal year 2023 results Pre-Market on Feb 29, 2024
Reported Earnings • Mar 10Full year 2022 earnings releasedFull year 2022 results: Revenue: €980.9m (up 9.9% from FY 2021). Net loss: €15.0m (loss narrowed 5.1% from FY 2021). Revenue is forecast to grow 5.2% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Pharmaceuticals industry in the United Kingdom.
お知らせ • Jan 12EUROAPI Announces Resignation of Corinne Le Goff as an Independent Member on the Board of DirectorsThe board of directors of EUROAPI announced Corinne Le Goff, after serving as an independent member on the board of directors since May 6, 2022, has resigned from her directorship as of January 11, 2023.
Buying Opportunity • Dec 08Now 29% undervalued after recent price dropOver the last 90 days, the stock is down 13%. The fair value is estimated to be €20.26, however this is not to be taken as a buy recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 5.4% per annum. Earnings is also forecast to grow by 32% per annum over the same time period.
Buying Opportunity • Nov 17Now 20% undervaluedOver the last 90 days, the stock is up 9.1%. The fair value is estimated to be €21.98, however this is not to be taken as a buy recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 5.4% per annum. Earnings is also forecast to grow by 31% per annum over the same time period.
お知らせ • Sep 01Euroapi S.A. to Report Fiscal Year 2022 Results on Mar 08, 2023Euroapi S.A. announced that they will report fiscal year 2022 results Pre-Market on Mar 08, 2023
